ABSTRACT
Objetivos: Determinar el riesgo clínico para desarrollar Hipertensión Arterial según la puntuación predictiva acorto plazo de Framingham en estudiantes de la carrera Médico y Cirujano del Centro Universitario de Oriente. Métodos: Este estudio evalúa el riesgo clínico de desarrollar Hipertensión Arterial en los próximos 4 años, según el score de riesgo de Framingham en los estudiantes de medicina del Centro Universitario de Oriente durante el año 2012. Resultados: Se presentan un riesgo global de 4.2 % según los criterios de Framingham para desarrollar hipertensión arterial en los próximos 4 años. Encontrando cinco veces másriesgo de desarrollar la enfermedad en el sexo masculino (3.58%) que para el sexo femenino (0.70%). Conclusiones: Los resultados muestran un riesgo importante de desarrollar Hipertensión Arterial a e da destempranas en los estudiantes de medicina del Centro Universitario de Oriente.
Objectives: to determine the clinical risk of developing hypertension according to the short-term predictive score Framingham students from the Medical School of Campus of Northwestern of Universidad de San Carlos (CUNORI). Methods: This study evaluates the clinical risk of Hypertension in the next 4 yearsaccording to the Framingham risk score in medical students of CUNORI in 2012. Results overall risk of 4.2%are presented according to the Framingham criteria for developing hypertension in the next 4 years. We Found five times the risk of developing the disease in males (3.58%) than for females (0.70%). Conclusions: The results show a significant risk of developing arterial hypertension at early ages in medical students of CUNORI.
Subject(s)
Humans , Hypertension/complications , Hypertension/diagnosis , Risk Factors , Students, MedicalABSTRACT
Studies were conducted to characterize the metabolic and dispositional fate of (14)C-tetrabromobisphenol A (TBBPA)-a commonly used brominated flame retardant, in male Fischer-344 rats. The percent of dose eliminated as total radioactivity in feces at 72 h following three different single oral doses (2, 20, or 200 mg/kg) of (14)C-TBBPA was 90% or greater for all doses. Most of the dose was eliminated in the first 24 h. At 72 h after administration of the highest dose, the amounts of (14)C found in the tissues were minimal (0.2-0.9%). With repeated daily oral doses (20 mg/kg) for 5 or 10 days, the cumulative percent dose eliminated in the feces was 85.1+/-2.8 and 97.9+/-1.1, respectively. In all studies radioactivity recovered in urine was minimal, <2%. Repeated dosing did not lead to retention in tissues. Following iv administration, feces was also the major route of elimination. Following iv administration of TBBPA, the radiolabel found in the blood decreased rapidly and could be described by a biexponential equation, consistent with a two-compartment model. The key calculated kinetic parameters are terminal elimination half-life (t(1/2)beta)=82 min; area under the blood concentration-time curve from time 0 to infinity (AUC)=1440 mug x min/ml; and apparent clearance (CL)=2.44 ml/min. Although readily absorbed from the gut, systemic bioavailability of TBBPA is low (<2%). It is extensively extracted and metabolized by the liver and the metabolites (glucuronides) exported into the bile. About 50% of an oral dose (20 mg/kg) was found in the bile within 2 h. This extensive extraction and metabolism by the liver greatly limits exposure of internal tissues to TBBPA following oral exposures.
